Fig. 2.
Signaling responses to HS-173 + afatinib in combination responsive and nonresponsive HNSCC cell lines. Western blot analysis of downstream PI3K and RAS-MEK-ERK pathway activation after 6-hour treatment with vehicle (DMSO), EGFR/ERBB2 inhibitor afatinib, PI3Kα inhibitor HS-173, and a combination in Cal-33, Detroit 562 and HSC-2 cell lines. HSP90 was used as a loading control. Representative images are shown.
